These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 20659364)

  • 1. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
    Dinger J; Assmann A; Möhner S; Minh TD
    J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
    Lete I; Chabbert-Buffet N; Jamin C; Lello S; Lobo P; Nappi RE; Pintiaux A
    Eur J Contracept Reprod Health Care; 2015; 20(5):329-43. PubMed ID: 26007631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
    Bird ST; Delaney JA; Etminan M; Brophy JM; Hartzema AG
    J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
    Dinger J; Do Minh T; Heinemann K
    Contraception; 2016 Oct; 94(4):328-39. PubMed ID: 27343748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel.
    Ahrendt HJ; Makalová D; Parke S; Mellinger U; Mansour D
    Contraception; 2009 Nov; 80(5):436-44. PubMed ID: 19835717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.
    Davis SR; Bitzer J; Giraldi A; Palacios S; Parke S; Serrani M; Mellinger U; Nappi RE
    J Sex Med; 2013 Dec; 10(12):3069-79. PubMed ID: 24034466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
    Junge W; Mellinger U; Parke S; Serrani M
    Clin Drug Investig; 2011; 31(8):573-584. PubMed ID: 21721593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.
    Larivée N; Suissa S; Coulombe J; Tagalakis V; Filion KB
    Drug Saf; 2017 Jul; 40(7):583-596. PubMed ID: 28382493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of four oral contraceptives on hemostatic parameters.
    Wiegratz I; Lee JH; Kutschera E; Winkler UH; Kuhl H
    Contraception; 2004 Aug; 70(2):97-106. PubMed ID: 15288212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel.
    Heinemann K; Heinemann LA
    J Fam Plann Reprod Health Care; 2011 Jul; 37(3):132-5. PubMed ID: 21659330
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA; Dinger J
    Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT; Zimmerman Y; Laan E; Termeer HMM; Appels N; Albert A; Fauser BCJM; Thijssen JHH; van Lunsen RHW
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.